Liber launched its closed-system NVP, Nicovape® Q in Australia in October 2021, marking it as the world’s first therapeutic NVP designed exclusively for prescription and dispensing through pharmacies.
After 2 1⁄2 years in the market, Liber has gathered comprehensive feedback on the product’s strengths and areas for improvement, not only for Nicovape® Q but for NVP technology as a whole. In response, Liber has completely reengineered Nicovape® Q to offer an exceptional and reliable user experience.
The new Nicovape® Q, which was launched in June 2024, complies with, and exceeds, the TGA’s revised standards set out in TGO 110, ensuring that it (i) is appropriate for therapeutic use and (ii) will maximise the likelihood of patient adherence.
In particular, the new Nicovape® Q boasts enhanced sensory features, increased cartridge and battery capacity, and a user portal accessible via NFC on any smartphone.
Nicovape® Q
Exceeding the new product standards for prescribed NVPs, Liber is delighted to announce the launch of its new Nicovape® Q range. The new Nicovape® Q provides an exceptional and reliable user experience via improved sensory aspects, increased cartridge and battery capacity, and a user portal available via NFC with any smartphone.
Enhanced user experience
- Optimised to deliver a best-in-class user experience
- NFC-enabled access to the mynicovape® Q portal
- In-use haptic feedback and for device status alerts
- 600mAh battery ensures a full day of use on a single charge
- Retains its minimised, discreet form-factor
- Touch-enabled USB-C port
Improved reliability
- Innovative design that protects against leakage, a significant cause of malfunction in vaping devices
- Enhanced microelectronics, including low-liquid notification and improved overheat protection
- Durable construction, which protects against scratching and malfunction from mistreatment
- Unique cartridge design with structural features to ensure shelf-life stability
Liber remains committed to seeking medical licensing for its new Nicovape® Q, which it produces in collaboration with an ISO 13485-certified medical device manufacturer.
Nicovape® Q50 | Q35 | Q20
Designed to meet new TGO 110 Standards
- New 50mg/ml concentration e-liquids
- Three flavours to meet new TGO 110 flavouring restrictions
- 2 ml cartridge capacity (33% increase), maximising value for your patients
Class-leading anti-counterfeiting technology
- Nicovape® Q only operates with authentic cartridges
- Guarantees traceability and transparency
Exceptional quality and testing
- Molecularly-characterised, pharmaceutical-standard and high-purity ingredients
- Extensive aerosol testing
- Improved protections to prevent aerosol contamination
New packaging designed for pharmacy distribution
- New innovative seven (7) cartridge package
- Individual blister packaging enables part dispensing to patients requiring less than a full box
mynicovape® Q
NFC-connected customer portal
Understanding the new regulatory framework and ensuring swift and ready access to dispensed NVPs has been a key hurdle to adoption and adherence. To address this, Liber has developed a new customer portal for patients, accessed by a simple tap of the Nicovape® Q device on any smartphone.
In terms of functionality, the mynicovape® Q portal allows users to:
- View remaining battery and e-liquid information;
- Access support resources, including live chat customer support;
- Track their usage over time, which allows greater transparency to help patients and doctors achieve therapeutic success; and
- Access prescribers for script renewal, and script management